Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient

References

• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14; discussion 1314–5. doi:10.1016/j.eururo.2006.09.019
   Web of Science ®Google Scholar
• Donaldson MM, Thompson JR, Matthews RJ, et al. The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn. 2006;25(7):709–716. doi:10.1002/nau.2023516998862
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766. doi:10.1046/j.1464-410x.2001.02228.x11412210
   PubMed Web of Science ®Google Scholar
• Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn. 2015;34(5):398–406. doi:10.1002/nau.2260224700771
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28(4):287. doi:10.1002/nau.2073719350662
   PubMedGoogle Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. doi:10.1002/nau.1005211857671
   PubMed Web of Science ®Google Scholar
• de Groat WC. The urothelium in overactive bladder: passive bystander or active participant? Urology. 2004;64(6 Suppl 1):7–11. doi:10.1016/j.urology.2004.08.06315621221
   PubMed Web of Science ®Google Scholar
• Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6A Suppl):57–67; discussion 68–73. doi:10.1016/S0090-4295(97)00591-8
   Web of Science ®Google Scholar
• Sakakibara R, Panicker J, Fowler CJ, et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol. 2014;21(1):33–38. doi:10.1111/iju.12288
   PubMed Web of Science ®Google Scholar
• Gibson W, Wagg A. Incontinence in the elderly, ‘normal’ ageing, or unaddressed pathology? Nat Rev Urol. 2017;14(7):440–448. doi:10.1038/nrurol.2017.5328401955
   PubMed Web of Science ®Google Scholar
• Gary B, Perera S, Murrin A, Aizenstein H, Tadic S. White matter hyperintensity burden and depression are associated with severity and impact of urgency urinary incontinence in functional, community-dwelling older women. Neurourol Urodyn. 2013;32(6):798–799.
   Web of Science ®Google Scholar
• NICE UK. Urinary Incontinence: The Management of Urinary Incontinence in Women (CG40); 2006.
   Google Scholar
• UK NICE. GC 97: the management of lower urinary tract symptoms in men; 2010 Available from: http://www.nice.org.uk/CG97. Accessed 327, 2020.
   Google Scholar
• Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142–E173. doi:10.5489/cuaj.458628503229
   PubMed Web of Science ®Google Scholar
• Wagg A. Treating overactive bladder in the elderly. Can Urol Assoc J. 2011;5(5 Suppl 2):S149–51. doi:10.5489/cuaj.1118821989530
   PubMed Web of Science ®Google Scholar
• Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002;8(19 Suppl):S598–607.12516954
   PubMed Web of Science ®Google Scholar
• Gibson W, Hunter KF, Camicioli R, et al. The association between lower urinary tract symptoms and falls: forming a theoretical model for a research agenda. Neurourol Urodyn. 2018;37(1):501–509. doi:10.1002/nau.2329528471525
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395. doi:10.1111/j.1464-410X.2008.07601.x18454794
   PubMed Web of Science ®Google Scholar
• Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367–374. doi:10.1093/ageing/26.5.3679351481
   PubMed Web of Science ®Google Scholar
• Teunissen D, van Weel C, Lagro-Janssen T. Urinary incontinence in older people living in the community: examining help-seeking behaviour. Br J Gen Pract. 2005;55(519):776–782.16212853
   PubMed Web of Science ®Google Scholar
• Shaw C, Tansey R, Jackson C, Hyde C, Allan R. Barriers to help seeking in people with urinary symptoms. Fam Pract. 2001;18(1):48–52. doi:10.1093/fampra/18.1.4811145628
   PubMed Web of Science ®Google Scholar
• Thompson IM, Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology. 1976;8(5):452–454. doi:10.1016/0090-4295(76)90273-9790746
   PubMedGoogle Scholar
• Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol. 1984;11(1–2):37–42.6370504
   PubMedGoogle Scholar
• Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991;145(4):813–6; discussion 816–7. doi:10.1016/S0022-5347(17)38459-8
   Web of Science ®Google Scholar
• Yoo DS, Han JY, Lee KS, Choo MS. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. Int J Clin Pract. 2012;66(2):132–138. doi:10.1111/j.1742-1241.2011.02838.x22188444
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93(3):303–310. doi:10.1111/j.1464-410X.2004.04606.x14764127
   PubMed Web of Science ®Google Scholar
• Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95(7):993–1001. doi:10.1111/j.1464-410X.2005.05454.x15839920
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212. doi:10.1016/j.eururo.2007.07.00917651893
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–585. doi:10.1111/j.1742-1241.2010.02626.x21489081
   PubMed Web of Science ®Google Scholar
• Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–320. doi:10.2217/1745509X.4.3.311
   Google Scholar
• Gibson W, Athanasopoulos A, Goldman H, et al. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence? Int J Clin Pract. 2014;68(9):1165–1173. doi:10.1111/ijcp.1244725196247
   PubMed Web of Science ®Google Scholar
• Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14(11):980–984. doi:10.1097/01.JGP.0000224619.87681.7117068321
   PubMed Web of Science ®Google Scholar
• Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–233. doi:10.2147/cia.S535819554093
   PubMed Web of Science ®Google Scholar
• Stuhec M. Solifenacin-induced delirium and hallucinations. Gen Hosp Psychiatry. 2013;35(6):682 e3–4. doi:10.1016/j.genhosppsych.2013.06.002
   Web of Science ®Google Scholar
• Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med. 2003;349(23):2274–2275. doi:10.1056/NEJM20031204349232514657444
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Michel MC, et al. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodyn. 2014;33(1):106–114.23460503
   PubMed Web of Science ®Google Scholar
• Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74–81. doi:10.1016/j.eururo.2013.01.00223332882
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–1300. doi:10.1111/j.1742-1241.2010.02433.x20561092
   PubMed Web of Science ®Google Scholar
• Michel MC. β-Adrenergic receptor subtypes in the urinary tract. Handb Exp Pharmacol. 2011;202:307–318.
   Google Scholar
• Bhide AA, Digesu GA, Fernando R, Khullar V. Mirabegron - a selective beta3-adrenoreceptor agonist for the treatment of overactive bladder. Res Rep Urol. 2012;4:41–45. doi:10.2147/RRU.S2893024199179
   PubMedGoogle Scholar
• Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, Placebo-controlled Phase 3 Study. Eur Urol. 2018;73(5):783–790. doi:10.1016/j.eururo.2017.12.02229366513
   PubMed Web of Science ®Google Scholar
• Keam SJ. Vibegron: first global approval. Drugs. 2018;78(17):1835–1839. doi:10.1007/s40265-018-1006-330411311
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448. doi:10.1517/17460441.2014.89292324559030
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–295. doi:10.1016/j.eururo.2012.10.01623182126
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–632. doi:10.1111/ijcp.1219423692526
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–320. doi:10.1016/j.urology.2013.02.07723769122
   PubMed Web of Science ®Google Scholar
• Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46(1):275–284. doi:10.1007/s11255-013-0509-923896942
   PubMed Web of Science ®Google Scholar
• Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666–675. doi:10.1093/ageing/afu01724610862
   PubMed Web of Science ®Google Scholar
• Wagg A, Staskin D, Engel E, et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 years with overactive bladder wet: a Phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 77(2):211–220.31733990
   PubMedGoogle Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–588. doi:10.1016/j.eururo.2014.02.01224612659
   PubMed Web of Science ®Google Scholar
• Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–575. doi:10.1111/bju.1388228418102
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre Phase 3B Study (BESIDE). Eur Urol. 2016;70(1):136–145. doi:10.1016/j.eururo.2016.02.03026965560
   PubMed Web of Science ®Google Scholar
• Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE Study. Eur Urol Focus. 2017;3(6):629–638. doi:10.1016/j.euf.2017.08.00828916436
   PubMedGoogle Scholar
• Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or Placebo. Eur Urol. 77(1):119–128.31635815
   PubMedGoogle Scholar
• Gratzke C, van Maanen R, Chapple C, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018;74(4):501–509. doi:10.1016/j.eururo.2018.05.00529866467
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745–755. doi:10.1093/ageing/afv07726104505
   PubMed Web of Science ®Google Scholar
• Chapple CR, Mironska E, Wagg A, et al. Multicriteria decision analysis applied to the clinical use of pharmacotherapy for overactive bladder symptom complex. Eur Urol Focus. 2019. doi:10.1016/j.euf.2019.09.020
   Google Scholar